VANCOUVER, BC, June 11, 2026 (GLOBE NEWSWIRE) -- VVT Med Inc. (TSXV:VVTM) ("VVT Med" or the "Company"), a developer of minimally invasive, non-thermal, non-tumescent ("NT-NT") solutions for venous disease, today announced its entry into the Dominican Republic market through a Trial Distribution and Evaluation Agreement (the "Agreement") with Antilles Medical ("Antilles"), a local distributor with established clinical and commercial infrastructure in the region.

Under the Agreement, Antilles has been appointed as VVT Med's exclusive distributor for ScleroSafe™ in the Dominican Republic for an initial evaluation period. The arrangement includes an initial purchase order for ScleroSafe Full Sets, reflecting Antilles' commercial commitment to the market entry process. The Agreement establishes a defined pathway to a full five-year exclusive distribution partnership, subject to the parties reaching mutually agreed terms prior to the conclusion of the evaluation period.

Antilles assumes full responsibilities as both distributor and importer under applicable local regulatory requirements, and its personnel are required to complete a comprehensive training and certification program provided by VVT Med prior to commencing any clinical activity. This structured onboarding model reflects VVT Med's commitment to quality-controlled commercial expansion and consistent clinical outcomes across markets.

"The Dominican Republic represents another step in our systematic expansion across the Americas," said Erez Tetro, Chief Executive Officer of VVT Med. "We are pleased to partner with Antilles Medical, whose local expertise and market knowledge support the introduction of ScleroSafe™ to local physicians. We look forward to supporting their team through training and clinical integration as we work toward a long-term commercial relationship."

This agreement extends VVT Med's growing commercial presence across the Americas, complementing the Company's established foothold in the United States through its relationship with Northwell Health, and its active distribution platforms in India and South Korea. The Dominican Republic entry follows the treatment of first patients in Italy in May 2026, underscoring the accelerating pace of ScleroSafe™ adoption among leading vein specialists globally.

Financing UpdateAs previously announced in the Company's news releases dated March 18, 2026 and April 22, 2026, the Company completed the first tranche of its non-brokered private placement offering of up to gross proceeds of $3,000,000 (the "Offering"), issuing 4,262,654 units (each, a "Unit") at a price of $0.25 per Unit ...